Table 2.
Treatment and prognosis data of 9 cases
| Case | Treatment | Chemotherapy regimens | Follow-up |
|---|---|---|---|
| 1 | Lobectomies | No | DOD, 34 mo. intrahepatic recurrence in the 19 mo, treated with TACE. Tumor metastasis in the 24 mo. |
| 2 | Lobectomies + Chemotherapy | MAID | FOD, 76 mo No recurrence |
| 3 | Lobectomies + Chemotherapy | MAID | FOD, 18 mo No recurrence |
| 4 | Lobectomies + Chemotherapy | MAID | FOD, 24 mo (recurrence in the 4mo ) |
| 5 | Lobectomies + Chemotherapy | MAID | FOD, 50 mo. (intrahepatic recurrence in the 29 mo. Treated with segmentectomy |
| 6 | Lobectomies + Chemotherapy | MAID | DOD, 47 mo. Intrahepatic recurrence in the 14 mo |
| 7 | Chemotherapy + TACE + Lobectomies | THP-ADM + CDDP | FOD, 29 mo. No recurrence |
| 8 | Lobectomies + Chemotherapy | MAID | FOD, 5 mo |
| 9 | Lobectomies + Chemotherapy | MAID | FOD, 5 mo |
DOD, dead of disease; FOD, free of disease; TACE, transcatheter arterial chemoembolization (lipiodol, epirubicin, and hydroxy camptothecin); MAID, mesna + adriamycin + iphosphamide + dacarbazine; THP-ADM, pirarubicin-adriamycin; CDDP, cis-diaminedichloroplatinum.